US4925787A - Monoclonal anti-idiotypic antibody, method for production thereof, and hybridoma producing said antibody ...
A monoclonal anti-idiotypic antibody specific to a human IgG 1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor; a method for the production of the aforementioned monoclonal anti-idiotypic antibody by the steps of immunizing an animal with a human IgG 1 type monoclonal antibody specific to nicotinic acetylcholine receptor, collecting antibody-producing cells from the animal, fusing the collected cells with neoplastic cells, selecting from the product of fusion a hybridoma capable of producing a monoclonal anti-idiotypic antibody specific to the human IgG 1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor, propagating the selected hybridoma thereby giving rise to said monoclonal anti-idiotypic antibody, and collecting the produced monoclonal anti-idiotypic antibody; and use of the monoclonal anti-idiotypic antibody as a reagent and as an adsorbent.
Patente US4925787 - Monoclonal anti-idiotypic antibody, method for production thereof, and ... - Google Patentes
A monoclonal anti-idiotypic antibody specific to a human IgG1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor; a method for the production of the aforementioned monoclonal anti-idiotypic antibody by the steps of immunizing an animal with a human IgG1 type monoclonal antibody specific to nicotinic acetylcholine receptor, collecting antibody-producing cells from the animal, fusing the collected cells with neoplastic cells, selecting from the product of fusion a hybridoma capable of producing a monoclonal anti-idiotypic antibody specific to the human IgG1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor, propagating the selected hybridoma thereby giving rise to said monoclonal anti-idiotypic antibody, and collecting the produced monoclonal anti-idiotypic antibody; and use of the monoclonal anti-idiotypic antibody as a reagent and as an adsorbent.
Specific Interference with the Determination of the Tumour-Associated Glycoprotein 72 by Human Anti-Idiotypic Antibodies Formed...
Specific Interference with the Determination of the Tumour-Associated Glycoprotein 72 by Human Anti-Idiotypic Antibodies Formed after Treatment with the Anti-Tumour-Associated Glycoprotein 72 Antibody ...
Characterization of anti-anti-idiotypic antibodies that bind antigen and an anti-idiotype (antigen mimicryythree-dimensional...
Two mouse monoclonal anti-anti-idiotopic antibodies (anti-anti-Id, Ab3), AF14 and AF52, were prepared by immunizing BALByc mice with rabbit polyclonal antiidiotypic antibodies (anti-Id, Ab2) raised against antibody D1.3 (Ab1) specific for the antigen hen egg lysozyme. AF14 and AF52 react with an internal image monoclonal mouse anti-Id antibody E5.2 (Ab2), previously raised against D1.3, with affinity constants (1.0 3 109 M21 and 2.4 3 107 M21, respectively) usually observed in secondary responses against protein antigens. They also react with the antigen but with lower affinity (1.8 3 106 M21 and 3.8 3 106 M21). This pattern of affinities for the anti-Id and for the antigen also was displayed by the sera of the immunized mice. The amino acid sequences of AF14 and AF52 are very close to that of D1.3. In particular, the amino acid side chains that contribute to contacts with both antigen and anti-Id are largely conserved in AF14 and AF52 compared with D1.3. Therapeutic immunizations against different
GMS | 27th German Cancer Congress Berlin 2006 | Molecular characterization of the anti-idiotypic immune response of a relapse...
Neuroblastoma treatment with chimeric anti-disialoganglioside GD2 antibody ch14.18 showed objective anti-tumor responses. Production of anti-idiotypic antibodies (Ab2) against ch14.18 (Ab1) in some cases was positively correlated with a more favorable prognosis. According to Jernes network theory, a subset of anti-idiotypic antibodies (Ab2beta) form an internal image of the antigen and induce antibodies (Ab3) against the original antigen. The molecular origin of the anti-idiotypic antibody response in tumor patients was not investigated previously. To clone anti-idiotypic antibodies, B-cells of a ch14.18-treated neuroblastoma patient with Ab2 serum reactivity were used to construct antibody phage display libraries (Methods described in Arthritis Rheum. 2000, 43:2722-2732). Upon repetitive selection of lambda and kappa Fab-phage display libraries on target antigens ch14.18 and the murine equivalent 14G2a, positive binders were enriched. Selected Ab2-clones GK2 and GK8 as well as another 38 ...
Idiotypic determinants of monoclonal antibodies that bind to 3-fucosyllactosamine. | The Journal of Immunology
Many monoclonal antibodies that react with the lacto-N-fucopentaose III (LNF III) antigenic determinant, Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4Glc, have been described recently. The terminal trisaccharide of this determinant, fucosyllactosamine, is present on glycolipids and glycoproteins and on the surface of granulocytes, monocytes, and other cells. To study the structural and genetic diversity of these antibodies, syngeneic anti-idiotypic monoclonal antibodies were produced in BALB/c mice against PMN 6, a monoclonal antibody directed against this sequence. Anti-idiotypic antibodies 6B1 and 6C4 reacted with 50% of a panel of 20 anti-LNF III monoclonal antibodies, whereas 6A3 reacted strongly only with PMN 6. This indicates that the determinants recognized by 6C4 and 6B1 represent major cross-reactive idiotopes of this family of antibodies. The binding of idiotypic antibodies to a glycolipid bearing this antigenic determinant was completely inhibited by the three anti-idiotypic ...
Identification of cell surface receptors for the 86-kilodalton glycoprotein of human cytomegalovirus | PNAS
Cell surface receptors for the 86-kDa glycoprotein (gp86) of human cytomegalovirus (HCMV) were identified by using two monoclonal anti-idiotype antibodies that bear the internal image of gp86. These antibodies bound to cells permissive for HCMV infection by both ELISA and immunofluorescence assay and inhibited HCMV plaque formation in human embryonic lung (HEL) cells. Immunoblot analysis showed specific binding of both internal image anti-idiotype antibodies as well as gp86 to an HEL cell membrane protein with an approximate molecular mass of 92.5 kDa. In addition, immunoprecipitation of radiolabeled membrane and cell surface proteins from human foreskin tissue, human foreskin fibroblasts, or HEL cells showed specific binding of anti-idiotype antibody predominantly to the 92.5-kDa protein.. ...
AB0497 Simultaneous determination of anti-infliximab antibodies and residual infliximab levels to monitor anti-TNF therapy |...
Results Anti-infliximab antibodies were detected in 21 patients (median: 131 ng/ml, range 10-200 ng/ml). Infliximab levels were weak in 25 patients (median: 0.16 microg/ml, range: ,0.1-0.41 microg/ml). In 20/25 patients (80%), the weak level of infliximab was associated to the presence of anti-infliximab antibodies. Interestingly, in sera of two patients obtained more than one year after the last infliximab perfusion, anti-infliximab antibodies were still present. Elevated infliximab levels were associated to the presence of anti-infliximab antibodies in only one patient. In 6 patients, the loss of infliximab response was not explained by the presence of anti-TNF antibodies or weak infliximab levels, suggesting that a switch to another biological agent could be more efficient than to another TNF inhibitor.. ...
The production of anti-idiotypic antibodies and of idiotype- -anti-idi by L M. Rose, M Goldman et al.
Rose, L M.; Goldman, M; and Lambert, P, The production of anti-idiotypic antibodies and of idiotype- -anti-idiotype immune complexes after polyclonal activation induced by bacterial lps. (1982). Subject Strain Bibliography 1982. 2727 ...
Brevet US5227159 - Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell ... - Google Brevets
B-cell lymphomas express surface immunoglobulin (immunoglobulin) containing unique idiotypic (idiotype) determinants which may be exploited as tumor specific markers. The inventor has produced murine monoclonal antibodies (MAbs) reactive with the idiotype marker derived from 67 patients with low grade, follicular, small cleaved cell lymphoma. Out of 199 monoclonal antibodies, 47 (24%) were found to react with pooled normal human serum immunoglobulin in concentrations ranging from 0.6 μg/ml to 160 μg/ml. Of these 40 monoclonal antibodies, 90% cross-reacted with idiotype present in normal serum in levels |50 μg/ml. Thirty-two of these anti-idiotypes were directed against a shared idiotope expressed on another patients lymphoma cells. The frequency of shared idiotope expression defined by each antibody ranged from 0.26% to 3.9% of the B-cell lymphomas tested. A panel of five anti-idiotype antibodies reacted with 80% of AIDS associated lymphomas. Based on the reactivity with these monoclonal antibodies,
Immunogenicity of Fab Fragment of Protein-315 for BALB/c Mice | The Journal of Immunology
Immunogenicity of Protein-315 and its Fab fragment (Fab-315) for isologous and heterologous strains of mice was investigated by comparing the characteristics of the anti-idiotypic response produced in BALB/c and A/J mice. The ability of these anti-idiotypic antisera to compete with DNP-lys for the ligand-binding site of Protein-315 were analyzed by comparing their hapten inhibition curves.. The anti-idiotypic responses of BALB/c mice to Protein-315 and to Fab-315 were similar to one another with regard to antibody specificity and sensitivity to inhibition by hapten, suggesting that both forms were equally immunogenic in inbred BALB/c mice. This observation indicates that the Fc portion of Protein-315 is not essential for the induction of anti-idiotypic response. Both BALB/c and A/J mice recognized the same antigenic determinants on Fab-315 since the anti-idiotypic antibodies produced by these animals were indistinguishable with regard to their interaction with Protein-315, Fv-315, and ...
Physicochemical and biological characterization of 1E10 Anti-Idiotype vaccine | BMC Biotechnology | Full Text
Anti-idiotype vaccination represents an innovative approach to target tumor-associated antigen-expressing cells. This approach comes directly from Jernes idiotypic network theory, which postulates that due to the huge potentiality for diversity of the immunoglobulin variable regions, the idiotype repertoire can mimic the universe of self and foreign epitopes [1].. NeuGc-containing gangliosides are attractive targets for cancer immunotherapy because these glycolipids are non-self antigens in humans [2, 3]. In contrast, they have been detected in different human tumors by antibodies and chemical analysis [4-6]. Recent experimental data suggest that N-glycolyl-GM3 ganglioside (NeuGcGM3) is relevant for tumor biology [7].. mAb-1E10 [8] is an IgG1 anti-idiotype (Ab2) mAb obtained by immunizing Balb/c mice with mAb-P3 (Ab1) [9] coupled to keyhole limpet hemocyanin (KLH) in the presence of Freunds adjuvant. This Ab2 inhibited the binding of mAb-P3 to NeuGcGM3 ganglioside. mAb-1E10 induced an ...
Induction of murine B cell proliferation by insolubilized anti-immunoglobulins<...
TY - JOUR. T1 - Induction of murine B cell proliferation by insolubilized anti-immunoglobulins. AU - Pure, E.. AU - Vitetta, E.. PY - 1980/1/1. Y1 - 1980/1/1. N2 - This study demonstrates that intact antibodies specific for μ, δ, or light chains when coupled to Sepharose are effective in delivering proliferative signals to B cells. Furthermore, using Sepharose-coupled anti-δ antibodies, we have shown that hybridoma anti-δ (that is not active as soluble protein) is as effective as rabbit anti-δ in activating murine B cells. However, antibodies directed against two other surface molecules, I-A and H-2K, were not mitogenic. Thus, sIgM and sIgD are comparable in their ability to transmit a proliferative signal to the B cell and sIg seems to play a unique role in this regard.. AB - This study demonstrates that intact antibodies specific for μ, δ, or light chains when coupled to Sepharose are effective in delivering proliferative signals to B cells. Furthermore, using Sepharose-coupled anti-δ ...
Perpetuation of immunological memory through common MHC-I binding modes of peptidomimic and antigenic peptides ePrints@IISc
Understanding the molecular mechanisms of immunological memory assumes importance in vaccine design. We had earlier hypothesized a mechanism for the maintenance of immunological memory through the operation of a network of idiotypic and anti-idiotypic antibodies (Ab2). Peptides derived from an internal image carrying anti-idiotypic antibody are hypothesized to facilitate the perpetuation of antigen specific T cell memory through similarity in peptide-MHC binding as that of the antigenic peptide. In the present work, the existence of such peptidomimics of the antigen in the Ab2 variable region and their similarity of MHC-I binding was examined by bioinformatics approaches. The analysis employing three known viral antigens and one tumor-associated antigen shows that peptidomimics from Ab2 variable regions have structurally similar MHC-I binding patterns as compared to antigenic peptides, indicating a structural basis for memory perpetuation. (C)) 2007 Elsevier Inc. All rights reserved.. ...
Xolair Endorsement Retracted by NICE - Clinical Professionals
The National Institute for Health and Clinical Excellence (NICE) have released draft guidance withdrawing their recommendation of Novartis Xolair for severe persistent allergic asthma.. In 2007, NICE circulated guidelines supporting the use of Xolair (omalizumab) on the National Health Service (NHS) for adults whose asthma is poorly controlled. Then in 2011 they reject the treatments use in children aged six to eleven years.. However, a review of the recommendations, in which new evidence, in particular new mortality data, was taken into account, has prompted the Institute to reject the medications use in both children and adults, as it is not as clinically and cost-effective as previously thought.. Alterations to the dosing schedule and the associated effect on Xolairs cost effectiveness were also taken into account, and this, along with doubts surrounding the evidence and analysis presented, did not support a positive recommendation for omalizumab, the cost watchdog noted.. The ...
The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
The physiology of anti-idiotypic interactions: From clonal to paratopic selection<...
TY - JOUR. T1 - The physiology of anti-idiotypic interactions. T2 - From clonal to paratopic selection. AU - Greally, John M.. PY - 1991. Y1 - 1991. N2 - On theoretical and experimental grounds, it has been proposed that the idiotypes of immunoglobulins and of T cell receptors are composed of multiple paratopes, as opposed to a single paratope and several idiotopes. This necessitates a revision of some of the basic principles of anti-idiotypic reactions. It is also possible to infer the presence of the same or similar paratopes on different idiotypes. A paratope cannot therefore be regarded as restricted to or unique on an idiotype. For these reasons, the perception of immunological specificity in terms of clonal units is misleading. This review proposes instead that the physiological unit of immunological specificity and regulation is the paratope. This essential alteration in the perception of the immune system is referred to as paratopic selection. The approach is assessed in terms of ...
Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice
BACKGROUND: Therapeutic idiotypic (Id) vaccination is an experimental treatment for selected B cell malignancies. A broader use of Id-based vaccinatio
VH gene expression is restricted in anti-IgG antibodies from MRL autoimmune mice. | JEM
Antibodies directed against IgG and DNA are found in the sera of autoimmune MRL/Mp lpr/lpr mice. Little is known of the molecular mechanisms underlying expression of such autoantibodies. We have investigated the binding diversity and pattern of VH gene expression in a panel of murine anti-IgG antibodies. We constructed eight hybridoma clones secreting IgM antibodies that bound to mouse IgG by using spleen cells from MRL/Mp lpr/lpr mice varying in age from 4 to 15 wk; one clone was derived from a 32-wk-old MRL +/+ mouse. The monoclonal IgM products exhibited varying binding specificities for intact mouse IgG, fragments of mouse IgG [Fc, Fab, (Fab)2], and heterologous IgG. Two of these antibodies crossreacted with B and/or Z DNA. Probes from seven of eight identified mouse VH gene families (7183, S107, Q52, J558, J606, 36-60, and 3609) were hybridized under high-stringency conditions with cytoplasmic RNA blots from each clone. Six clones hybridized only with the probe from the five-member 36-60 ...
Injections for Severe Allergic Asthma
Injections may be a helpful add-on treatment for certain people with severe allergic asthma. Learn more about how it works, how much it costs, and some of the potential side effects.
Catalysis of ecterilysis by anti-idiotypic antibody towards acetylcholinesterase - Fingerprint - UC Davis
E. S. Aleksandrova, F. Koralewski, M. I. Titov, A. V. Demin, A. N. Ignatova, A. V. Kozyr, A. V. Kolesnikov, A. Tramontano, S. Paul, D. Thomas, A. G. Gabibov, A. Friboulet ...
Induction and characterization of autologous anti-idiotypic antibodi by H Cosenza, A Augustin et al.
Cosenza, H; Augustin, A; and Julius, M H., Induction and characterization of autologous anti-idiotypic antibodies. (1977). Subject Strain Bibliography 1977. 3483 ...
Plus it
We conceived this study to challenge, in the light of current knowledge, the tacit assumption that omalizumab therapy is of no clinical benefit in conventionally defined, non-atopic asthmatics. In lieu of a large, long-term, conventional clinical trial in the first instance, which would have been difficult to fund given the paucity of supportive evidence, we elected to provide proof of concept that omalizumab therapy of these patients reduces IgE expression and IgE sensitisation of target cells within the bronchial mucosa while exerting a favourable effect on lung function in the short term, as assessed by changes in FEV1. We obtained bronchial biopsies before and after 12-14 weeks of treatment with omalizumab or placebo while maintaining existing therapy, reasoning that any differences in mucosal cell populations between the active and placebo cohorts observed under these conditions would be attributable to omalizumab. We set changes in mucosal IgE+ cells as a co-primary outcome measure, ...
Download Antibody Techniques by Vedpal S. Malik, Erik P. Lillehoj PDF - 12 dqvt Books
A 13-amino-acid motif in the cytoplasmic domain of FcyRIIB modulates B-cell receptor signalling. Nature (London) 368, 7 0 - 7 3 . , and Lamoyi, E. (1981). Implications of the presence of an internal image of the antigen in anti-idiotypic antibodies: Possible application to vaccine production. Clin. Immunol. Immunopathol. 21, 397. Noelle, R. J . , and Snow, E. C. (1991). T helper cell-dependent B cell activation. FASEB J. 5, 2770-2776. Nossal, G. J. V. (1994). Negative selection of lymphocytes. Cell 76, 2 2 9 - 2 3 9 . Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science 262, 1011-1018. Finkelman, F. , Holmes, J . , Katona, I. , Urban, J. F . , Beckmann, M. , Park, L. , Schooley, K. , Coffman, R. L . , Mosmann, T. , and Paul, W. E. (1990). Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 8, 3 0 3 - 3 3 3 . Fiorentino, D. F . , Bond, M. , and Mossman, T. R. (1989). Two types of mouse helper T cell. IV. Th2 clones ...
P88 Real-Life Experience of Omalizumab in Children with Severe Asthma | Thorax
Results 33 children (22 male) aged 5-16 years were commenced on omalizumab. At 16 weeks there were significant improvements in mini-AQLQ; ACT; FENO; maintenance OCS dose; severe exacerbations and UHCVs.. 20/33 (60.6%) children continued omalizumab beyond the initial 16 weeks (up to 192 weeks). Compared to those who discontinued, at baseline these children had higher mini-AQLQ (4.28 vs. 3.05) and ACT (11 vs. 8), were younger (11 vs. 13 years) and were more likely to have been admitted to hospital (57.9% vs. 0%) and have had a severe exacerbation (95% vs. 50%) in the 16 weeks before starting omalizumab. Maximal reduction in number of exacerbations and hospital admissions was evident at 32 weeks; this was maintained for up to 144 weeks (Figure 1).. ...
Anti Golimumab Antibody, clone AbD25455 | Bio-Rad Antibodies (formerly AbD Serotec)
Human Anti-Golimumab Antibody, clone AbD25455 is an anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug goli
Anti Nivolumab Antibody, clone AbD30255 | Bio-Rad
|strong|Human Anti-Nivolumab Antibody, clone AbD30255|/strong| is a paratope specific, inhibitory anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug nivolumab. The antib…
UPENN Biomedical Graduate Studies | Dorothee Herlyn
Our laboratory is developing cancer vaccines that are being evaluated in animal models for their protective activity against tumors before they are administered to cancer patients. The vaccines are composed of antibodies mimicking tumor antigens (anti-idiotypic antibodies) or the antigens expressed in viruses (recombinant adeno- or vaccinia-viruses) and are selected based on their high probability of inducing both humoral and cellular immune responses in patients. The animal models we have developed for preclinical evaluation of the vaccines closely mimic the condition in cancer patients. In other studies which have reached clinical trials, we are evaluating the vaccinated patients immune responses to their tumors ...
Omalizumab
Omalizumab Omalizumab? Therapeutic monoclonal antibody Source Humanized Target IgE Identifiers CAS number 242138-07-4 ATC code R03DX05 PubChem ? DrugBank
Development of anti-infliximab antibody is associated with reduced efficacy and infusion reaction in Behçets disease with...
Mean serum IFX trough level was 4.4+ 4.7mg/ml in 430 samples from 122 patients. The level was significantly lower in symptomatic phase (n=73, 2.5±5.3 μg/ml) than in the asymptomatic phase (n=357, 4.9 ± 4.6μg/ml). ROC analysis determined the cut-off level was 0.93μg/ml. Patient-based analysis revealed that the trough level was lower in Group C+D (1.3±3.3μg/ml) than Group A (4.2±4.4μg/ml) and B (5.4±5.7μg/ml), whereas administration interval was significantly shorter in Group B (7.2±1.1 wk) and C+D (6.8±1.5 wk) than Group A (8.2±0.9 wk). ATI(+) was found in 18 (11.3%) of all patients. The frequency was significantly higher in Group C+D (5/10, 50%) and E (4/8, 50%) than Group A (3/75, 4%) and B (6/38, 16%). Thus, unfavorable clinical responses were associated with low trough level and positive ATI. Muitivariate analysis using logistic regression model revealed association of therapeutic failure (Group C+D and E) with female, positive ATI, and infusion reaction (IR). Moreover, ATI was ...
JCI - Tregs in T cell vaccination: exploring the regulation of regulation
T cell vaccination (TCV) activates Tregs of 2 kinds: anti-idiotypic (anti-id) and anti-ergotypic (anti-erg). These regulators furnish a useful view of the physiology of T cell regulation of the immune response. Anti-id Tregs recognize specific effector clones by their unique TCR CDR3 peptides; anti-id networks of CD4+ and CD8+ Tregs have been described in detail. Here we shall focus on anti-erg T regulators. Anti-erg T cells, unlike anti-id T cells, do not recognize the clonal identity of effector T cells; rather, anti-erg T cells recognize the state of activation of target effector T cells, irrespective of their TCR specificity. We consider several features of anti-erg T cells: their ontogeny, subset markers, and target ergotope molecules; mechanisms by which they regulate other T cells; mechanisms by which they get regulated; and therapeutic prospects for anti-erg upregulation and downregulation.. ...
OPUS Würzburg | Search
The responsiveness to IL-4 with and without costimulation with anti-IgM antibodies or phorbolester was studied in 35 cases of low grade non-Hodgkin Iymphoma by analyzing enhancement of CD23 and HLA dass li expression. The predominant phenotype responds directly to IL-4. Separate differentiation states can be distinguished according to coordinate or differential upregulation of CD23 and HLA dass II molecules by IL-4 alone, and differences in responsiveness to anti-IgM antibodies. A particular subgroup of B-lymphoma cells defines a separate stage of B-eeil differentiation. They fail to express high affinity binding sites for IL-4 and accordingly do not respond to IL-4- mediated signals. Cross-linking membrane lgM receptors or direct activation of protein kinase C via phorbolester induces IL-4 receptor expression and subsequent IL-4 reactivity ...
OPUS Würzburg | Search
The responsiveness to IL-4 with and without costimulation with anti-IgM antibodies or phorbolester was studied in 35 cases of low grade non-Hodgkin Iymphoma by analyzing enhancement of CD23 and HLA dass li expression. The predominant phenotype responds directly to IL-4. Separate differentiation states can be distinguished according to coordinate or differential upregulation of CD23 and HLA dass II molecules by IL-4 alone, and differences in responsiveness to anti-IgM antibodies. A particular subgroup of B-lymphoma cells defines a separate stage of B-eeil differentiation. They fail to express high affinity binding sites for IL-4 and accordingly do not respond to IL-4- mediated signals. Cross-linking membrane lgM receptors or direct activation of protein kinase C via phorbolester induces IL-4 receptor expression and subsequent IL-4 reactivity ...
訪問學者專家
我們的研究主軸是利用抗體工程技術來開發新藥。這些以抗體為結構基礎的藥物,主要標的牽涉於IgE引致的過敏反應過程。我們也積極從事開發可提升抗體工程 的數種創新技術平台。其中一項研究計畫就是要發展人源化、高親和力,及對人體膜IgE分子內CεmX具結合特異性的抗體,以用來控制表現IgE的B淋巴細 胞。CεmX是張教授的研究群發現的;它是一含有具特異序列的52個氨基酸長的胜肽區段。如發展成功,anti-CεmX可與張教授發明的anti-IgE,如已在美國等國核准上市用於嚴重哮喘的omalizumab(商名Xolair),共同使用。. ...
Pall ForteBio :: Dip and Read™ Anti-Murine IgG Quantitation (AMQ) Biosensors
ForteBios Anti-Murine IgG Quantitation biosensors provide a rapid method for precise quantitation of murine immunoglobulins from crude lysates and cell culture supernatants. For Determination of Antibody Concentration
CD4 Rat anti-Murine, Brilliant Ultraviolet 737, Clone: GK1.5, BD Horizon | Fisher Scientific
Shop a large selection of products and learn more about CD4 Rat anti-Murine, Brilliant Ultraviolet 737, Clone: GK1.5, BD Horizon 50 µg; BUV737.
anti-ID4 antibody (N-Term) | Product No. ABIN2780374
Rabbit Polyclonal ID4 antibody N-Term for WB. Published in 2 Pubmed References. Order this anti-ID4 antibody. | Product number ABIN2780374
Anti-gamma H2A.X (phospho S139) antibody - ChIP Grade (ab2893) Protocols
Abcam provides specific protocols for Anti-gamma H2A.X (phospho S139) antibody - ChIP Grade (ab2893) : ChIP protocols, Immunoprecipitation protocols…
Anti-gamma H2A.X (phospho S139) antibody [9F3] (ab26350) References
Anti-gamma H2A.X (phospho S139) antibody [9F3] (ab26350) has been cited in 47 publications. References for Human, Mouse, Rat, Dog, Pig in ICC, ICC/IF, IF, IHC…
P3AGI: Workpackages description
The progression of this project, as well as the outcomes, will be extremely relevant to the public and scientific researchers since Severe Allergic Asthma is a common disease worldwide. AA is well documented and the public already have a great deal of understanding and so are more likely to be interested in new advances in research related to this condition. The objectives of this work package are to ...
CENPE肽(ab45476)|Abcam中国
购买我们的CENPE肽。ab45476可作为ab27470的封闭肽并经过Blocking实验验证。Abcam提供免费的实验方案,操作技巧及专业的支持。中国80%以上现货。
Anti-Filamin A抗体(ab11074)参考文献| Abcam中国官方网站
引用Abcams Anti-Filamin A抗体(ab11074)的参考文献列表。为您列举引用本产品的发表文章,并提供信息包括论文文献数据库中的检索编号以便您搜寻文章
Host Anti-antibody Responses Following Adeno-associated Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus...
TY - JOUR. T1 - Host Anti-antibody Responses Following Adeno-associated Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys. AU - Martinez-Navio, José M.. AU - Fuchs, Sebastian P.. AU - Pedreño-López, Sònia. AU - Rakasz, Eva G.. AU - Gao, Guangping. AU - Desrosiers, Ronald C.. PY - 2015/10/7. Y1 - 2015/10/7. N2 - Long-term delivery of antibodies against the human immunodeficiency virus (HIV) using adeno-associated virus (AAV) vectors is a promising approach for the prevention or treatment of HIV infection. However, host antibody responses to the delivered antibody are a serious concern that could significantly limit the applicability of this approach. Here, we describe the dynamics and characteristics of the anti-antibody responses in monkeys that received either rhesus anti-simian immunodeficiency virus (SIV) antibodies (4L6 or 5L7) in prevention trials or a combination of rhesusized human anti-HIV antibodies (1NC9/8ANC195/3BNC117 or 10-1074/10E8/3BNC117) in therapy ...
Effects of Omalizumab Treatment on Some Biomarkers in Severe Allergic Asthma Patients [Eurasian J Pulmonol]
Methods: Consecutive patients with severe asthma disease (n=15; Group IA, pretreatment and Group IB, post-treatment) underwent omalizumab treatment. Control group was age- and sex-matched including 25 healthy in Group II. Blood samples from both the groups were taken during their first visit (Group IA and II) and then after 12 months of treatment in asthmatic patients (Group IB). Serum levels of homocysteine (Hcy), eosinophil cationic peptide (ECP), 25-hydroxyvitamin D (25(OH)D), interleukin-1β (IL-1β), soluble OX2 (sCD200) and clinical follow-up tests including fractional exhaled nitric oxide (FeNO), asthma control test (ACT), and pulmonary function tests were evaluated ...
BIOmarkers in Severe AsthMa Patients on Omalizumab Treatment - Tabular View - ClinicalTrials.gov
Anti-IgE (omalizumab) has been shown to be an effective add-on therapy for patients with allergic severe asthma. In this observational study patients aged over 18 year with uncontrolled severe persistent asthma are selected for add-on therapy with omalizumab. Patients were on high dose of ICS and had a documented history of 2-6 exacerbations requiring treatment with systemic corticosteroids ( with ,15 mg/day prednisone or other medications at similar dose, for at least 3 days). The individual dose and frequency of omalizumab administration is assessed from the dosing table. Lung function tests and asthma questionnaires (ACQ, AQLQ and RQLQ) are used in the aim of assessing clinical improvement after omalizumab treatment. Induced sputum (IS) and exhaled breath condensate (EBC) are used as a simple non-invasive methods for monitoring cellular and biochemical changes in the airways. Total blood eosinophil count, IS cytology, IS and EBC periostin and IL-6 concentrations are measured. Analyses are ...
Basiliximab, Novartis Pharmaceutical Corp - Package Insert
General It is not known whether Simulect use will have a long-term effect on the ability of the immune system to respond to antigens first encountered during Simulect -induced immunosuppression. Immunogenicity Of renal transplantation patients treated with Simulect and tested for anti-idiotype antibodies, 4/339 developed an anti-idiotype antibody response, with no deleterious clinical effect upon the patient. In none of these cases was there evidence that the presence of anti-idiotype antibody accelerated Simulect clearance or decreased the period of receptor saturation. In Study 2, the incidence of human anti-murine antibody (HAMA) in renal transplantation patients treated with Simulect was 2/138 in patients not exposed to muromonab-CD3 and 4/34 in patients who subsequently received muromonab-CD3. The available clinical data on the use of muromonab-CD3 in patients previously treated with Simulect suggest that subsequent use of muromonab-CD3 or other murine anti-lymphocytic antibody preparations ...
T cell activity in successful treatment of chronic urticaria with omalizumab | Clinical and Molecular Allergy | Full Text
Omalizumab, a humanized monoclonal anti-IgE antibody has the potential to alter allergen processing. Recently, it has been postulated the assessment of PHA-stimulated adenosine triphosphate (ATP) activity as maker of CD4+ T cells activity in peripheral blood cells. We present the case report of a 35-year-old woman with a history of chronic idiopathic urticaria and angioedema of 8 years of development with poor response to treatment. The patient was partially controlled with cyclosporine at doses of 100 mg/12 h. However, she was still developing hives daily. Finally treatment with omalizumab was started at dose of 300 mg every 2 weeks. The patient experienced a decrease in urticarial lesions 2 days after starting therapy. We also evaluated the effects of omalizumab therapy on the activity of peripheral blood CD4+ T cells from the patient, in order to determine the potential modification of anti-IgE therapy on the process of antigen presentation-recognition. Activity of CD4+ cells by ATP release was
QUANTITATIVE INVESTIGATIONS OF IDIOTYPIC ANTIBODIES | JEM
Rabbit anti-idiotypic antibodies were prepared by injection of specifically purified anti-p-azobenzoate antibodies (D) from individual donor rabbits. Benzoate derivatives were found to be strong inhibitors of the reactions of D with anti-D antisera. There was a close correlation between the combining affinities of the benzoate derivatives used and their effectiveness as inhibitors. Compounds tested that are chemically unrelated to benzoate were ineffective. The results indicate either that the combining site of anti-benzoate antibody is part of an important idiotypic determinant, which is sterically blocked by hapten, or that the hapten induces a conformational change which alters idiotypic determinants not involving the active site. Such conformational changes, if they occur, must be restricted since hapten has little effect on the reactions of F(ab)2 fragments of anti-benzoate antibodies with antisera directed to rabbit fragment Fab and no detectable effect on reactions with antibodies ...
anti-Immunoglobulin G, Immunoglobulin M (IgG, IgM) (Heavy & Light Chain) antibody (Alkaline Phosphatase (AP)) ABIN637975 from...
anti-Immunoglobulin G, Immunoglobulin M (IgG, IgM) (Heavy & Light Chain) antibody (Alkaline Phosphatase (AP)) ABIN637975 from antibodies-online
A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma - Full Text View - ClinicalTrials.gov
Deterioration of asthma upon withdrawal of Xolair as demonstrated by meeting at least one of the following: *Worsening of pulmonary function tests (FEV1 ,80% predicted for height, age, and sex) and activity levels while off Xolair treatment; *Worsening of asthma exacerbations defined as doubling of inhaled steroid dose, increase in dose of oral steroids, or initiation of oral, intravenous, intramuscular, or subcutaneous (SC) steroids while off Xolair treatment; *Increased use of rescue medications while off Xolair treatment; *ER visits or unscheduled office visits for asthma that may or may not result in hospitalization while off Xolair ...
An Algorithm to Guide the Rational, Evidence-Based Use of Omalizumab in the Treatment of Chronic Urticaria | Actas Dermo...
Omalizumab is a monoclonal anti-IgE antibody currently used in the treatment of chronic spontaneous urticaria (CSU) as a third-line option in cases refractory to treatment with the licensed dose of the first-line treatment or up to 4 times that dose. The introduction of omalizumab into the therapeutic arsenal for CSU brought about a real revolution in the management of this condition. However, the dose recommended in the Summary of Product Characteristics-based on the results of pivotal studies carried out as part of the approval process-is 300 mg/mo for a period of up to 6 months. In the present issue, the Catalan-Balearic working group presents a treatment algorithm to guide the use of omalizumab in the management of CSU. They discuss the various aspects of management related to the rational and evidence-based use of this drug, including candidate population, monitoring tools (Urticaria Activity Score 7 [UAS7] and Urticarial Control Test [UCT]), starting dose and dose adjustment as well as the ...
Metabolomic applied to omalizumab effect in severe asthmatics - a preliminary result | Clinical and Translational Allergy |...
Case report: We present the case of a 48 year old woman, with severe persistent allergic asthma, despite level 4 (GINA) medical treatment, who initiated omalizumab in order to control her nocturnal symptoms and her frequent unscheduled medical visits. Before treatment and at 12 weeks: clinical evaluation with ACT was registered; lung function, FeNO, IgE and eosinophils were measured. Two-dimensional gas chromatography (GC ´GC-ToFMS) combined with headspace solid phase microextraction (HS-SPME) was applied to the untargeted study of the volatile metabolomic urine profile. ...
IL-12 R beta 1 Goat anti-Mouse, Polyclonal, R&D Systems™ 100μg; Unlabeled IL-12 R beta 1 Goat anti-Mouse, Polyclonal, R&D...
IL-12 R beta 1 Goat anti-Mouse, Polyclonal, R&D Systems™ 100μg; Unlabeled IL-12 R beta 1 Goat anti-Mouse, Polyclonal, R&D Systems™ Primary...
2001 - Omalizumab reduced inhaled corticosteroid use and exacerbations in childhood allergic asthma | 2002 Jan-Feb :...
The study by Milgrom and colleagues is their second on the use of omalizumab (anti-IgE antibody) in the treatment of asthma and the third published in the past 3 months that addresses treatment with anti-IgE in large, multicenter asthma studies. Concurrent studies by Busse and colleagues (1) and Soler and colleagues (2) included , 500 adult patients aged 12 to 75 years and used medium to high-dose inhaled steroids (500 to 1200 µg/d of beclomethasone). They used a design similar to that of Milgrom and colleagues and achieved similar results in terms of steroid reduction and decreases in exacerbations. These studies, along with an earlier publication by Milgrom and colleagues (3), make a case for anti-IgE antibodies as adjunctive treatment for steroid-dependent patients with asthma. The advantages of anti-IgE over conventional therapies include once or twice-monthly subcutaneous injections and its tolerability with infrequent side effects. However, many questions remain. Although the association ...
Omalizumab - Side Effects, Uses, Dosage, Overdose, Pregnancy, Alcohol | RxWiki
Omalizumab - Get up-to-date information on Omalizumab side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about Omalizumab
Anti-Human IgE scFv Stable Cell Line-CHO CSC-P0250 - Creative BioMart
Gentaur Molecular :ICL \ anti-Human IgE Unconjugated A.P. Host Mouse \ ME-80A
Gentaur molecular products has all kinds of products like :search , ICL \ anti-Human IgE Unconjugated A.P. Host Mouse \ ME-80A for more molecular products just contact us
Anti-Human IgG, IgA, IgE Antibodies
Anti-Human IgG Fc and IgE are purified mouse monoclonal antibodies. The goat anti-human IgG and IgA are affinity purified polyclonal antibodies.
Abstract for Manuscript Number [849]
Author(s): Markus Brede ,Ulrich Behn Subject(s): CX.3 Category: Abstract:. The talk deals with modelling a subsystem of the immune system, the so-called idiotypic network. Idiotypic networks, a concept conceived by N.K. Jerne in 1974, are functional networks of interacting antibodies and B-cells. In principle, Jernes framework provides solutions to many issues in immunology, such as immunological memory, mechanisms for antigen recognition and the question of self/non-self discrimination. Explaining the interconnection between the elementary components local dynamics, network formation and architecture, and possible modes of global system function appears to be an ideal playground of statistical mechanics. We present a simple cellular automaton model based on a graph representation of the system. From a simplified description of idiotypic interactions rules for the random evolution of networks of occupied and empty sites on these graphs are derived. In certain biologically relevant parameter ...
Omalizumab Protects Against Early, Late Allergic Responses --Doctors Lounge
THURSDAY, June 8, 2017 (HealthDay News) -- For patients with a significant response to allergen challenge, omalizumab induces protective effects against early (EAR) and late allergic reactions (LAR), according to a study published online June 5 in Allergy.. Jordis Trischler, M.D., from the University Hospital Frankfurt in Germany, and colleagues determined the time course of the early (EAR) and late allergic reaction (LAR). Ten patients with a significant response to allergen challenge were treated with omalizumab. At week one, two, four, and eight, bronchial allergen provocations were repeated.. The researchers observed a significant reduction in EAR after four weeks (change in forced expiratory volume in one second [ΔFEV1], 28 versus 11 percent; P , 0.001; exhaled nitric oxide, 86 versus 53 ppb; P , 0.05), and there was a reduction in basophil activation after two weeks (CD63 expression, 79 versus 32 percent; P , 0.05). After one week there was a reduction in LAR (ΔFEV1, 26 versus 13 ...
Cortisol PM, LAB2384 - St. Lukes Hospital Cedar Rapids
Container/Tube:. Preferred: Green-top (lithium heparin) tube. Acceptable: Gold-top serum gel tube or Plain Red-top tube. Specimen Volume: 170 uL of plasma or serum. Stability: Keep tubes stoppered and upright at all times. Do not use samples that have been stored at room temperature for longer than 8 hours. Tightly cap and refrigerate specimens at 2° to 8°C if the assay is not completed within 8 hours. Freeze samples at or below -20°C if the sample is not assayed within 48 hours. Freeze samples only once and mix thoroughly after thawing. Collection Instructions:. Note: 1. Human anti-mouse antibodies or other heterophile antibodies may be present in patient specimens. This assay has been specially formulated to minimize the effects of these antibodies, however results from patients known to have these antibodies should be carefully evaluated.. 2. Label specimen appropriately (plasma/serum).. ...
Goat anti-Mouse IgM, HRP
Goat anti-Mouse IgM Secondary Antibody, HRP conjugate from Invitrogen for Western Blot, Immunocytochemistry and Immunohistochemistry applications. Supplied as 2 mL purified secondary antibody (0.8 mg/ml) in PBS with 15mg/ml BSA and no preservative; pH 7.6.
JoVE Author Search: Aarden LA
Antibodies, Treatment, Human, Patients, Plasma, Serum, Igg, Immunoglobulin, Monoclonal Antibodies, Therapeutic, Anti-idiotype Antibodies, Breast, Breast Cancer, Calibration, Cancer, Elisa, Enzyme-linked Immunosorbent Assay, Horseradish, Horseradish Peroxidase, Immunoassay
XOLAIR S.C. INJ 75MG/0.5ML
Buy XOLAIR S.C. INJ 75MG/0.5ML (OMALIZUMAB) from ADV-Care Pharmacy, a Canadian mail order Online pharmacy since 2000. Offers best prices And expedite shipping XOLAIR S.C. INJ by TEVA CANADA LIMITED .
Nazarbayev University Repository
The basic components of the diagnostic test systems are antigens and specific antibodies. The main objective of developing express tests for the diagnosis of bovine leukemia virus (BLV) is to obtain a virus antigen drug, which is very time-consuming to prepare. This problem can be solved by producing anti-idiotype antibodies that have a chemical structure identical to that of the viral antigen and does not require large expenditures to manufacture [1, 2 ...
2020 PharmSci 360
Methods: The Gyros platform was used to develop immunoassays for the active and total TAb. For active/free Tab immunoassays, biotinylated target protein or biotinylated anti-TAb mAb (paratope-specific anti-idiotypic (ID) Ab) was used as a capture reagent and AlexaFluor647-labeled anti-TAb mAB (non-blocking anti-ID Ab) was used for detection. For the total assay, biotinylated mouse anti-human IgG (Fc specific) mAb was used to capture the TAb and AlexaFluor647 labeled mouse anti-human IgG (kappa light chain specific) mAb was used as a detection reagent. The assays were used for the bioanalysis of monkey serum samples ...
anti-Human IgG antibody, pre-adsorbed (TxRd) | GeneTex
Human IgG antibody, pre-adsorbed (TxRd) for ELISA, FACS, ICC/IF. Anti-Human IgG pAb (GTX27151) is tested in Human samples. 100% Ab-Assurance.
Omalizumab Dosage Guide + Max Dose, Adjustments - Drugs.com
Detailed Omalizumab dosage information for adults and children. Includes dosages for Asthma - Maintenance and Urticaria; plus renal, liver and dialysis adjustments.
Xolair Side Effects in Detail - Drugs.com
Learn about the potential side effects of Xolair (omalizumab). Includes common and rare side effects information for consumers and healthcare professionals.
Geoscience Research Institute | A Critique of Current Anti-ID Arguments and ID Responses
This paper evaluates a representative sample of the best anti-ID and pro-ID publications and presents a conclusion as to the present state of the evidence and arguments regarding these positions. Published in Origins, n. 63.
Tímea Pekárová - NeL.edu
Raffáč Š, Gombošová L, Gabzdilová J, Novotná L, Šajtyová K, Pekárová T, Kopolovets I, Tóth Š. Detection of anti-infliximab antibodies in Slovak IBD patients and its costs saving effect. Neuro Endocrinol Lett. 2017 Nov; 38(Suppl1): 5-9 ...
Goat Anti-Mouse HYPB / SETD2 (internal region), (internal region) [ER-14-0723]
Specificityinternal regionStorage/StabilityAliquot and store at -20°C Minimize freezing and thawing More InformationImmunogenThe immunogen was a 12-residue peptide matching a sequence from the internal region of Mouse SETD2 See Accession Number s NP_054878 3 Formulation 0 5 mg/ml in TBS 0
Goat Anti-Mouse Robo1 / DUTT1 (mouse), (internal region) [ER-14-1247]
Specificityinternal regionStorage/StabilityAliquot and store at -20°C Minimize freezing and thawing More InformationImmunogenThe immunogen was a 12-residue peptide matching a sequence from the internal region of Mouse Robo1 See Accession Number s NP_062286 2 Formulation 0 5 mg/ml in TBS 0
Anti-Murine IL-9 Polyclonal Antibody from Active Bioscience
PLCγ1 Antibody (Ab-771), pAb, Rabbit 中国教育装备采购网
GenScriptRabbitAnti-PLCγ1(Ab-771)PolyclonalAntibodydetectsendogenouslevelsoftotalPLCγ1protein.FullNamePLCγ1Antibody(Ab-771),pAb,Rabbitabbreviated_name1PLC-γ1(Ab-771)AntibodyIgS
Xolair Administration
Pt presents to office with Asthma and is treated with Zolair. Since Zolair is considered a monoclonal antibody, what is the appropriate administration
CAR阳性表达率检测 ACROBiosystems中国
CAR阳性表达率检测是CAR-T疗法质量控制的重要一环,常用的检测方案有利用Protein L、Anti-Fab抗体或靶点蛋白结合流式细胞术进行检测。其中,靶点蛋白结合流式细胞术的检测方案因其靶点特异性强的优势而备受青睐,许多业内人士预期靶点特异性的检测将会被监管机构纳入CAR-T质量控制监管考量的范畴。本文将对CAR阳性表达率检测相关案例做一汇总以供大家参考..
FOCIS 2019
CU patients treated with Omalizumab, showed lower percentage of CD4+HLA-DR+CD38+[0,75(0,6-1,1)vs1,23(1,01-1,54)%,p,0,0001], CD4+DR+CD38-[1,7(0,7-3,15)vs3,07(2,5-4,7)%,p=0,0006] and higher percentage of CD8+DR-CD38+ [14±2 vs 8±0,5%,p=0,0001] and Th1 CM [12±0,8 vs 9±0,4%, p,0,0001] than HD.. ...
Euhesmaalbamala sp. n.: A-D Allotype male genital str | Open-i
Euhesmaalbamala sp. n.: A-D Allotype male genital structures: A genital ventral B genital dorsal C S7+S8 ventral D S7+S8 dorsal. Scale bars: 200 µm.